Results 171 to 180 of about 2,461 (207)

Formulation and evaluation of stimuli-sensitive hydrogels of timolol maleate and brimonidine tartrate for the treatment of glaucoma.

Int J Pharm Investig, 2014
Dubey A, Prabhu P.
europepmc   +1 more source

Periorbital skin hypopigmentation associated with the use of topical glaucoma medications. [PDF]

Digit J Ophthalmol
Karimaghaei S, Yee J, Elhusseiny AM.
europepmc   +1 more source

The Effect of Ocular Hypotensive Medications on Posterior Segment Blood Flow in Healthy Subjects: A Prospective, Randomized, and Interventional Study. [PDF]

J Curr Ophthalmol
Shokouhi Rad S, Ghannad M, Shoeibi N, Bakhtiari E, Heidarzadeh HR.   +4 more
europepmc   +1 more source

Recent advances and future challenges in nanosystems for ocular drug delivery. [PDF]

J Pharmacol Exp Ther
Shahror RA, Fouda AY.
europepmc   +1 more source

Successful treatment of glaucoma in Sturge-Weber syndrome using PreserFlo™ microshunt with intraluminal stenting: a case report. [PDF]

Am J Ophthalmol Case Rep
Inami H, Tomita R, Yuki K.
europepmc   +1 more source

Topical Drug Treatment of Rosacea in Switzerland: A Descriptive Study Using Swiss Claims Data.

Dermatology
Zappalà T, Navarini AA, Huber CA, Meier CR, Spoendlin J.   +4 more
europepmc   +1 more source

Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate

Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate
openaire  

Some of the next articles are maybe not open access.

Related searches:

Brimonidine tartrate for the treatment of glaucoma

Expert Opinion on Pharmacotherapy, 2018
Brimonidine tartrate is a commonly used eyedrop for short- and long-term lowering of intraocular pressure. Its use has been popularized due to its effects on aqueous suppression and uveoscleral outflow, as well as the suggestion of neuroprotection. Although available with alternative preservative vehicles, brimonidine is associated with high rates of ...
Daniel J, Oh, Judy L, Chen, Thasarat S, Vajaranant, Mark S, Dikopf   +3 more
openaire   +2 more sources

Advances in Glaucoma Therapy: Brimonidine Tartrate

Seminars in Ophthalmology, 1997
Brimonidine, a newly approved α2-adrenoceptor agonist, is a 2-imidazoline derivative which is more highly selective for the α2-adrenoceptor than either clonidine or apraclonidine. The mechanism of action by which it lowers intraocular pressure (IOP) involves a decrease in aqueous humor production and an increase in aqueous humor outflow through the ...
David S. Greenfield, Jeffrey M. Liebmann, Robert Ritch   +2 more
openaire   +1 more source